Axtria Launches LUCCID to Transform Clinical Data Management with GenAI
Delivers Technology for Automating Unstructured Clinical Data Extraction with Over 90% Accuracy BERKELEY HEIGHTS, N.J., April 29, 2025 /PRNewswire/ --...
Clinical Trial
Axtria Launches LUCCID to Transform Clinical Data Management with GenAI
Delivers Technology for Automating Unstructured Clinical Data Extraction with Over 90% Accuracy BERKELEY HEIGHTS, N.J., April 29, 2025 /PRNewswire/ --...
ProofPilot Announces Strategic Partnership with the Digital Medicine Society to Advance Digital Health in Clinical Trials
NEW YORK, April 29, 2025 /PRNewswire/ -- ProofPilot, the industry's first end-to-end Clinical Experience Platform (CXP), purpose-built for recruitment and...
ProofPilot Announces Strategic Partnership with the Digital Medicine Society to Advance Digital Health in Clinical Trials
NEW YORK, April 29, 2025 /PRNewswire/ -- ProofPilot, the industry's first end-to-end Clinical Experience Platform (CXP), purpose-built for recruitment and...
Avant Technologies and Ainnova Request Pre-Submission Meeting with US FDA for VisionAI Platform Technology
LAS VEGAS, April 29, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), and its JV partner,...
Lirum Therapeutics’ LX-101 New Positive Data Selected for Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting
New York, NY, April 29, 2025 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on...
Rakovina Therapeutics Showcases Preclinical Results of Novel AI-Discovered Cancer Therapies at AACR 2025
Data highlights novel PARP1 and ATR inhibitors with progress toward next-generation therapies for hard-to-treat malignanciesVANCOUVER, British Columbia, April 29, 2025...
Rakovina Therapeutics Showcases Preclinical Results of Novel AI-Discovered Cancer Therapies at AACR 2025
Data highlights novel PARP1 and ATR inhibitors with progress toward next-generation therapies for hard-to-treat malignanciesVANCOUVER, British Columbia, April 29, 2025...
Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting
Updated clinical and preclinical data showcase iPSC-derived off-the-shelf CAR T-cell therapy products for conditioning chemotherapy-free treatment across autoimmune and cancer...
Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting
Updated clinical and preclinical data showcase iPSC-derived off-the-shelf CAR T-cell therapy products for conditioning chemotherapy-free treatment across autoimmune and cancer...
Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon
Orchestra BioMed’s Virtue® Sirolimus AngioInfusion Balloon™ (“Virtue SAB”) is the only non-coated drug-eluting balloon system under clinical investigation worldwide and has...
Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon
Orchestra BioMed’s Virtue® Sirolimus AngioInfusion Balloon™ (“Virtue SAB”) is the only non-coated drug-eluting balloon system under clinical investigation worldwide and has...
Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer
Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025Annamycin is potentially a highly versatile drug capable...
Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer
Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025Annamycin is potentially a highly versatile drug capable...
Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025
SOUTH SAN FRANCISCO, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company...
Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025
SOUTH SAN FRANCISCO, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company...
CytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich, Germany
Dr. Jacob Lalezari, CEO, and Dr. Richard Pestell, Lead Consultant in Preclinical and Clinical Oncology, to lead CytoDyn group in...
CytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich, Germany
Dr. Jacob Lalezari, CEO, and Dr. Richard Pestell, Lead Consultant in Preclinical and Clinical Oncology, to lead CytoDyn group in...
First Major U.S. Commercial Health Insurer Approves Purchase of ReWalk 7 Personal Exoskeleton
Approval signals important progress in U.S. market expansion as major commercial health insurers begin to follow precedent set with Medicare...
First Major U.S. Commercial Health Insurer Approves Purchase of ReWalk 7 Personal Exoskeleton
Approval signals important progress in U.S. market expansion as major commercial health insurers begin to follow precedent set with Medicare...